JD Health International (SEHK:6618) Could Be 43% Undervalued As Half Year Profit Rises
Why JD Health International’s Latest Earnings Matter For Investors
JD Health International (SEHK:6618) drew fresh attention after reporting half year 2026 earnings, with higher sales, net income and earnings per share compared with the same period a year earlier.
See our latest analysis for JD Health International.
Despite the stronger half year earnings, JD Health International’s share price tells a mixed story. The stock is at HK$38.66 after a 1 day share price return of 1.63%, yet the year to date share price return is down 31.39% and the 1 year total shareholder return is down 39.12%. This suggests that recent momentum is still weak compared with earlier years.
If you are reassessing your exposure to digital healthcare after JD Health International’s results, this can be a moment to look at other opportunities in the sector through 129 healthcare AI stocks.
Given JD Health International’s solid half year figures but weak longer term share returns, you need to judge whether the stock is now pricing in business progress or mostly reflecting cautious sentiment. The valuation metrics give the next clues.
Most Popular Narrative: 43.3% Undervalued
At a last close of HK$38.66 versus a narrative fair value of HK$68.17, JD Health International is framed as materially undervalued, with that gap anchored to long term earnings and margin expectations using a 7.18% discount rate.
Rapid acceleration in AI integration across medical consultations, diagnostics, and service delivery is driving higher operational efficiency, elevated user satisfaction, and improved conversion rates, supporting upward momentum in both revenue and net margins.
Want to see what kind of revenue path and margin profile would justify that higher fair value for JD Health International? The narrative leans on steady top line expansion, a specific earnings target and a richer future earnings multiple that assumes the platform’s scale really pays off.
Result: Fair Value of HK$68.17 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, analysts also flag rising competition in Chinese digital healthcare and potential regulatory shifts around medical insurance payments that could limit JD Health International’s earnings power.
Find out about the key risks to this JD Health International narrative.
Another View On JD Health International’s Valuation
The narrative fair value frames JD Health International as 43.3% undervalued at HK$68.17, yet the P/E picture is more nuanced. The stock trades on 17x earnings, above the Asian Consumer Retailing industry at 15.7x, but below a fair ratio of 21x that the market could move toward. That mix of relative expensiveness to the sector and discount to the fair ratio raises a simple question: Is the current price compensating you enough for the business risks and execution hurdles ahead?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
After weighing JD Health International’s recent earnings and valuation signals, it makes sense to pressure test the optimism and risks against your own expectations. To see what the market currently views as the key upside drivers, take a closer look at the 3 key rewards.
Looking for more investment ideas beyond JD Health International?
If JD Health International’s story has you rethinking your portfolio, this is a good moment to broaden your watchlist using focused stock ideas from the Simply Wall St screener.
- Spot underappreciated quality by reviewing companies flagged as 267 high quality undervalued stocks that might offer a more attractive entry point than the broader market.
- Strengthen your income stream through stocks in the 424 dividend fortresses that aim to combine higher yields with resilience.
- Prioritise resilience first by checking companies in the 291 resilient stocks with low risk scores that score well on stability and downside protection.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com